Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROPEL: PK-guided BAX 855 prophylaxis in severe hemophilia A
NCT02585960Phase 3Completed
- Sponsor
- Takeda
- Start
- Nov 2015
- Primary completion
- Aug 2018
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes
- Countries
- 22
01
Overview
A Phase 3 trial of rurioctocog alfa pegol in hemophilia A, sponsored by Takeda. Started Nov 2015; status: completed.
02
Drugs
rurioctocog alfa pegol
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT02585960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02585960.